Back to results
TerminatedPhase 2Phase 3

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT04857359

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Xenosciences Inc

Phoenix, Arizona, United States

+40 additional locations

View on ClinicalTrials.gov
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy — TrialFind